(+)-ITD-1 is a resolved enantiomer of ITD-1 that possesses a greater than 2-fold increase in TGF-β inhibition (~400 nM) and 1.3-fold increase in cardiogenesis compared to the racemic ITD-1. (+)-ITD-1 is largely responsible for TGF-β pathway-selective inhibition that inhibits TGF-β activity by selectively degrading the TGF-β2 receptor at the proteosome level. (+)-ITD-1 does not block the closely related Activin A signaling pathway. (+)-ITD-1 has been formulated as a salt to increase stability and improve water solubility (~0.1 mg/mL) for ease of handling. As a salt, ITD-1 is chemically and metabolically stable and can be used to study a wide range of biological questions in cellular processing and TGF-β signaling.
Technical information:
| Chemical Formula: | C27H29NO3 | |
| CAS #: | N/A | |
| Molecular Weight: | 415.52 | |
| Purity: | >98% | |
| Appearance: | Yellow solid | |
| Chemical Name: | ethyl 4-([1,1'-biphenyl]-4-yl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylate | |
| Solubility: | Up to 50 mM in DMSO |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Willems E, et al. Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells. Cell Stem Cell. 2012;11(2):242-52. PMID: 22862949 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
